Publication:
Human monoclonal ScFv specific to NS1 protein inhibits replication of influenza viruses across types and subtypes

dc.contributor.authorRungrueang Yodsheewanen_US
dc.contributor.authorSanti Maneewatchen_US
dc.contributor.authorPotjanee Srimanoteen_US
dc.contributor.authorKanyarat Thueng-Inen_US
dc.contributor.authorThaweesak Songsermen_US
dc.contributor.authorFonthip Dong-Din-Onen_US
dc.contributor.authorKunan Bangphoomien_US
dc.contributor.authorNitat Sookrungen_US
dc.contributor.authorKiattawee Choowongkomonen_US
dc.contributor.authorWanpen Chaicumpaen_US
dc.contributor.otherMahidol Universityen_US
dc.contributor.otherThammasat Universityen_US
dc.contributor.otherKasetsart Universityen_US
dc.date.accessioned2018-10-19T05:01:31Z
dc.date.available2018-10-19T05:01:31Z
dc.date.issued2013-09-13en_US
dc.description.abstractCurrently, there is a need of new anti-influenza agents that target influenza virus proteins other than ion channel M2 and neuraminidase. Non-structural protein-1 (NS1) is a highly conserved multifunctional protein which is indispensable for the virus replication cycle. In this study, fully human single chain antibody fragments (HuScFv) that bound specifically to recombinant and native NS1 were produced from three huscfv-phagemid transformed Escherichia coli clones (nos. 3, 10 and 11) selected from a human ScFv phage display library. Western blot analysis, mimotope searching/epitope identification, homology modeling/molecular docking and phage mimotope ELISA inhibition indicated that HuScFv of clone no. 3 reacted with NS1 R domain important for host innate immunity suppression; HuScFv of clone nos. 10 and 11 bound to E domain sites necessary for NS1 binding to the host eIF4GI and CPSF30, respectively. The HuScFv of all clones could enter the influenza virus infected cells and interfered with the NS1 activities leading to replication inhibition of viruses belonging to various heterologous A subtypes and type B by 2-64-fold as semi-quantified by hemagglutination assay. Influenza virus infected cells treated with representative HuScFv (clone 10) had up-expression of IRF3 and IFN-β genes by 14.75 and 4.95-fold, respectively, in comparison with the controls, indicating that the antibodies could restore the host innate immune response. The fully human single chain antibodies have high potential for developing further as a safe (adjunctive) therapeutic agent for mitigating, if not abrogating, severe symptoms of influenza. © 2013 Elsevier B.V. All rights reserved.en_US
dc.identifier.citationAntiviral Research. Vol.100, No.1 (2013), 226-237en_US
dc.identifier.doi10.1016/j.antiviral.2013.07.019en_US
dc.identifier.issn18729096en_US
dc.identifier.issn01663542en_US
dc.identifier.other2-s2.0-84883607745en_US
dc.identifier.urihttps://repository.li.mahidol.ac.th/handle/20.500.14594/31870
dc.rightsMahidol Universityen_US
dc.rights.holderSCOPUSen_US
dc.source.urihttps://www.scopus.com/inward/record.uri?partnerID=HzOxMe3b&scp=84883607745&origin=inwarden_US
dc.subjectImmunology and Microbiologyen_US
dc.subjectPharmacology, Toxicology and Pharmaceuticsen_US
dc.titleHuman monoclonal ScFv specific to NS1 protein inhibits replication of influenza viruses across types and subtypesen_US
dc.typeArticleen_US
dspace.entity.typePublication
mu.datasource.scopushttps://www.scopus.com/inward/record.uri?partnerID=HzOxMe3b&scp=84883607745&origin=inwarden_US

Files

Collections